|
|
 |
|
Viewing report
|
|
|
|
Melanoma Therapeutics: Which Strategy Will Take Us There?
Bioseeker, July 2005, Pages: 204
We have identified more than 120 companies within the sphere of melanoma and we have listed the biggest players within this field below:
Abgenix, Actis Biologics, Ajinomoto, Amgen, Anosys, Antigen Express, Antigenics, Antisense Pharma, Applied Molecular Evolution, Arriani, AVAX Technologies, Avidex, BASF, Bayer, Biokine, bioMerieux, Biomira, Bioniche, BioNumerik, BioWa, BioVex, Bristol-Myers Squibb, Callisto, CancerVax, Celgene, CelSci, Chiron, Chugai, CJ Corp, Clavis, Coley Pharmaceutical, Corixa, CSL, Curacyte, CuraGen, Cytokinetics, Discovery Laboratories, Elan, ELEA, Enichimica, EntreMed, Enzon, GemVax, Genencor, Genentech, Generex Biotechnology, Genetronics, GenQuest, Genta, Genzyme, Gilead Sciences, GlaxoSmithKline, GlobeImmune, Hayashibara, IDM, ImClone Systems, Inotek, Intercell, Intracel, Introgen, Juvaris, KeyCell, Kirin Brewery, KOSAN, KuDOS, Kyowa Hakko, Ligand, Lilly, Lorus Therapeutics, Maxim, Medarex, Medigen Biotechnology, MedImmune, Megapharm, Merck KGaA, Mojave, Myriad, Novartis, Novo Nordisk, Onyx, Orient Europharma, Oxxon, Pfizer, PharmaMar, Pharmexa, Pierre Fabre, Pisa, Point Therapeutics, Progen, Inovio Biomedical Corporation, RegeneRx, Roche, Russian Biotechnologies, Sanofi-aventis, Scancell, Schering-Plough, SciClone, Sclavo, Sequenom, Serono, Sigma-Tau, T-cellic, Therion Biologics, Titan, Transgene, Valentis, VaxGen, Vernalis, Vical, Viragen, ViraNative, Viventia Biotech, Wyeth, ZymoGenetics and more.
Customers who bought this item also bought
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Gene Therapy - Technologies, Markets and Companies
Disease and Therapy Review: Melanoma
Stakeholder Opinions: Malignant Melanoma - High Hurdles, High Rewards, Are Vaccines Only Skin Deep?
Triple Analysis: Decoding Big Pharma's R&D Strategy in Oncology and Special Focus Lung Cancer and Melanoma
Strategic Perspectives: Malignant Melanoma - Biotechnology-Driven Agents Finding a Flagship Indication?
Stakeholder Opinions: Melanoma - Lucrative Commercial Opportunities Persist
Currently Druggable in Melanoma: A Drug Target Competitive Analysis
Cell Therapy - Technologies, Markets and Companies
Cancer Cell Therapy Markets
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC
Gene Therapy - Global Strategic Business Report
|
|
|
|
